A Study of HR071603(Ketamine Nasal Spray) in Healthy Subjects

Overview

The study is being conducted to evaluate the safety and pharmacokinetics of HR071603 in healthy subjects.

Full Title of Study: “Safety, Tolerance and Pharmacokinetics of Hydrochloric Acid (R) -Ketamine Nasal Spray in Healthy Subjects: A Randomized, Double Blind, Placebo-Controlled Phase I Clinical Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: June 1, 2021

Interventions

  • Drug: HR071603
    • HR071603 monotherapy ,nasal spray
  • Drug: placebo
    • placebo,nasal spray

Arms, Groups and Cohorts

  • Experimental: Treatment group A
    • HR071603,nasal spray,dose escalation.
  • Placebo Comparator: Treatment group B
    • Placebo, nasal spray

Clinical Trial Outcome Measures

Primary Measures

  • Incidence of Adverse Events (Safety and Tolerability)
    • Time Frame: Pre-dose to Day8

Secondary Measures

  • Assessment of PK parameter-Area under drug-time curve (AUC)
    • Time Frame: Pre-dose to Day2
  • Assessment of PK parameter-peak time (Tmax)
    • Time Frame: Pre-dose to Day2
  • Assessment of PK parameter-peak concentration (Cmax)
    • Time Frame: Pre-dose to Day2
  • Assessment of PK parameter-half-life (t1/2)
    • Time Frame: Pre-dose to Day2
  • Assessment of PK parameter-apparent clearance rate (CL/F)
    • Time Frame: Pre-dose to Day2
  • Assessment of PK parameter-apparent distribution volume (Vz/F)
    • Time Frame: Pre-dose to Day2

Participating in This Clinical Trial

Inclusion Criteria

1. Obtain informed consent prior to the start of any activity related to the trial, and have a thorough understanding of the purpose and meaning of the trial and be willing to comply with the protocol; 2. Healthy males aged between 18 and 45 (including both ends); 3. Weight ≥ 50kg, body mass index (BMI) in the range of 18.5 ~ 23.9 (including both ends); 4. During the trial and within 30 days after the administration, willing to take contraceptive measures and ensure that no sperm is donated. Exclusion Criteria:

1. A subject considered by the investigator to be unsuitable for nasal spray administration; 2. Allergic to any component of the study drug; 3. The underlying disease is not suitable for participation in the trial; 4. 12-lead ECG results in the screening period are abnormal and clinically significant 5. Liver dysfunction; 6. Serum creatinine > 1.2 × ULN during screening period; 7. Screening for infectious diseases screening hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), syphilis antibody, human immunodeficiency virus (HIV) antibody test positive; 8. Subject has been thoroughly examined, and the results are abnormal and clinically significant; 9. Major operations were performed within 3 months before the screening period. 10. Donate whole blood/plasma within one month before the screening period, or donate whole blood/plasma more than 400 ml within three months before the screening period; 11. Positive urine drug test; 12. The alcohol breath test is positive; or the average daily intake of alcohol exceeds 15g; 13. Nicotine test is positive; 14. History of drug abuse or alcohol abuse; 15. In the past three months, over five cups of coffee or tea per day were consumed in an average; 16. Any prescription drugs, over-the-counter drugs and health products were used within 2 weeks before screening. 17. Participated in clinical trials of any drug or medical device within 3 months before screening ; 18. Any other medical or psychological condition, which in the opinion of the Investigator, might create undue risk to the participant or interfere with the participant's ability to comply with the protocol requirements, or to complete the study.

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Jiangsu HengRui Medicine Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.